CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from ...
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic ...
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) Monday announced that the European Medicines Agency or EMA has accepted the marketing authorization application for its tofersen for the treatment of ...
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1 QALSODY is Biogen’s third rare disease therapy to be approved in ...
Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline of neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1 With QALSODY, Biogen has advanced the role of neurofilament in the ...
Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALS Over 3 years, a subset of QALSODY-treated participants ...
Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALS Over 3 years, a subset of QALSODY-treated participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback